It is very uncertain whether imiquimod changes complete clearance compared with placebo (very low certainty).
Imiquimod showed no clear difference in recurrence during compared with any other patient‐applied treatment (low certainty).
It is very uncertain whether imiquimod changes any local reactions during therapy compared with any other patient‐applied treatment (very low certainty).
Imiquimod may leads to lower any systemic reactions during therapy compared with any other patient‐applied treatment (low certainty).
It is very uncertain whether imiquimod changes complete clearance compared with any other provider‐administered treatment (very low certainty).
It is very uncertain whether imiquimod changes recurrence during compared with any other provider‐administered treatment (very low certainty).
It is very uncertain whether imiquimod changes pain during therapy compared with any other provider‐administered treatment (very low certainty).
It is very uncertain whether imiquimod changes any local reactions during therapy compared with any other provider‐administered treatment (very low certainty).
It is very uncertain whether imiquimod changes partial clearance compared with placebo (very low certainty).
It is very uncertain whether imiquimod changes recurrence during compared with placebo (very low certainty).
It is very uncertain whether imiquimod changes appearance of new warts during treatment compared with placebo (very low certainty).
It is very uncertain whether imiquimod changes any local reactions during therapy compared with placebo (very low certainty).
Imiquimod showed no clear difference in any systemic reactions during therapy compared with placebo (low certainty).
Imiquimod may leads to higher pain during therapy compared with placebo (low certainty).
It is very uncertain whether imiquimod changes complete clearance compared with any other patient‐applied treatment (very low certainty).
Imiquimod showed no clear difference in partial clearance compared with any other patient‐applied treatment (low certainty).
The review found no eligible studies for this question.
Imiquimod probably leads to higher recurrence at 3 years compared with surgical excision (moderate certainty).
Imiquimod may leads to higher cosmetic outcome (good/excellent) compared with surgical excision (low certainty).
Imiquimod showed no clear difference in pain (moderate/severe) compared with surgical excision (low certainty).
The findings closest to your search, judged one by one by TypeSafe's Jev model.